Business
Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy
Appointment Strengthens Clinical Leadership in Precision Fluid Management and Acute Kidney Injury MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis,
About this update from Nuwellis, Inc.
[{"type":"text","content":"Appointment Strengthens Clinical Leadership in Precision Fluid Management and Acute Kidney Injury\nMINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understanding of acute kidney injury (AKI), fluid overload, and the use of continuous renal replacement therapies in critically ill children. Dr. Goldstein’s research has been foundational in demonstrating the relationship between fluid overload and mortality in critically ill pediatric patients, including landmark studies through the Prospective Pediatric Continuous Renal Replacement Therapy Registry. His work has significantly shaped global standards for early identification and management of AKI and fluid balance in critically ill populations. As Director of Clinical Strategy , Dr. Goldstein will consult with and advise Nuwellis on clinical feedback, product development, pediatric innovation, evidence generation, and educational initiatives aligned with the company’s evolving cardiorenal focus. His expertise will directly support Nuwellis’ commitment to advancing precision fluid management solutions that address the critical interplay between the heart and kidneys across the continuum of care. “Our cardiorenal strategy is rooted in the science of fluid balance and the clinical consequences of fluid overload,” said Kelsey Newell, Sr. Director of Medical Affairs at Nuwellis. “Dr. Goldstein’s pioneering work in pediatric AKI and fluid management has shaped how the medical community understands the impact of fluid overload on outcomes. His insight will strengthen our clinical evidence roadmap, guide responsible innovation, and ensure our technologies are aligned with the needs of critically ill children and adults.” Dr. Goldstein added, “Fluid overload remai...